Murine retrovirus-induced spongiform encephalopathy: disease expression is dependent on postnatal development of the central nervous system.
In this report, we have examined the role of central nervous system (CNS) development in the pathogenesis of neurodegenerative disease induced by murine retroviruses. This was accomplished by comparing the effect of delivering viruses, with either severe or marginal neurovirulence (J. L. Portis, S. Czub, C. F. Garon, and F. J. McAtee, J. Virol. 64:1648-1656, 1990), during the midgestational development of the mouse (gestation days 9 to 10). Midgestation inoculation of the marginally neurovirulent virus, 15-1, resulted in high level CNS infection, as determined by viral DNA and protein analysis. The high-level infection resulted in rapid, severe disease with 100% incidence and an average clinical onset on postnatal day 17 (P17). The disease onset was comparable to that observed for the highly neurovirulent virus, FrCasE, when inoculated neonatally (onset ca. P16). To evaluate whether disease could be induced even earlier in CNS development, FrCasE was inoculated during midgestation. Surprisingly, neither clinical nor histological manifestations of CNS disease were accelerated but rather appeared at the same developmental time as seen for neonatally inoculated animals (onset of neuropathology at ca. P10; onset of clinical disease at ca. P15). CNS infection, on the other hand, occurred at earlier times (< P0), at higher levels, and with a broader distribution than in neonatally inoculated animals. No infection of the neurons which ultimately degenerate was observed in any regimen of virus inoculation. It was observed, however, that the gp70 viral envelope protein from the CNS showed an increase mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis compared with the envelope protein from infected spleens or purified virions. These results indicate that a postnatal developmental event must occur to allow the presence of a neurovirulent virus to precipitate spongiform degeneration and that an altered envelope protein may be participating in the process.
Lynch
W P
WP
Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, Montana 59840.
Portis
J L
JL
D000818:Animals; D000831:Animals, Newborn; D001921:Brain / Q000254:growth & development / Q000382:microbiology / Q000473:pathology; D002490:Central Nervous System / Q000254:growth & development / Q000382:microbiology* / Q000473:pathology; D015686:Gene Products, env / Q000302:isolation & purification; D007150:Immunohistochemistry; D051379:Mice / Q000196:embryology / Q000382:microbiology; D009474:Neurons / Q000473:pathology; D012190:Retroviridae / Q000254:growth & development / Q000472:pathogenicity*; D012192:Retroviridae Infections / Q000209:etiology / Q000473:pathology*; D012376:Rodent Diseases / Q000209:etiology / Q000382:microbiology* / Q000473:pathology; D013997:Time Factors; D014018:Tissue Distribution; D014774:Virulence; D014779:Virus Replication
D015686:Gene Products, env